A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER-
2004 ◽
Vol 22
(14_suppl)
◽
pp. 728-728
◽
Keyword(s):
Phase Ii
◽